The Study Of Merger Integration Risk Mangment In Pharmaceutical Fields

According to the forecast of U.S. authorities pharmaceutical consulting firm IMS, The overall size of China’s pharmaceutical industry will become the world’s second largest pharmaceutical market by2015. If the CAGR is calculated about the rate of20percent, China’s pharmaceutical market will be amout to the U.S. market nowdays until10to15years. Although the market has great potential, the current China’s pharmaceutical industry preached "multiple, small, scattered, chaotic" feature:pharmaceutical companies up to13,000, pharmaceutical commercial enterprises reached420,000. the proportion of generic drugs as much as90%.But pharmaceutical products is a knowledge-based products, the model of "Drug+IPR=huge profits" which makes drug development, pharmaceutical companies patent is essential. and the feature of drug development which led the situation of R&D capabilities more worse. homogeneous competition is particularly seriously. While with multinational pharmaceutical companies on the market continue to strengthen control, it began to take more and more mergers and acquisitions, sole proprietorship, etc. Under the background of the serious competition, most of pharmaceutical companies take merger integration strategy.While there are various of risks in the process of merger integration, Huayuan、 SangJiu and other domestic pharmaceutical companies are all result of failure. Although the record is not good, yet there are lots of successors, such as Hualun Pharma companies acquisition. Suddenly, we found Fosun Pharma the company who is succeed in merger integration. Therefore, this passage choose Fosun Pharma as the target of our analysis, summarize the key point of risk management in merger integration, and set proper principles for the target which reduce the risk of strategy taking, rights integration, management integration, affair integration and so on.For example, pre-merger integrated focused on the strategy formulation of the development of the field of medicine, and merger integration process taken to guard against the risk of wrong property, the risk of management integration and business integration,in order to improve the ratio of domestic pharmaceutical companies.